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Available online 11 June 2016The mucopolysaccharidoses are a group of inherited metabolic diseases caused by deﬁciencies in enzymes
involved in the sequential degradation of glycosaminoglycans (GAGs) leading to substrate accumulation in
various tissues and organs. GAG accumulation can cause growth retardation and progressive damage to respira-
tory, cardiovascular, musculoskeletal, nervous, gastrointestinal, auditory, and visual systems. In the past, few
people with severe phenotypic mucopolysaccharidosis (MPS) reached adulthood. However, better methods for
diagnosis, multi-disciplinary care, and new therapies have extended lifespan, leading to an increasing number
of patients surviving beyond childhood. The growing number of adult MPS patients poses signiﬁcant challenges
for clinicians who may not be familiar with the clinical manifestations of MPS. In addition, as new interventions
have changed the natural history of these disorders, it is difﬁcult to anticipate both the impact on life expectancy
and other complications that may occur as these patients age. Because the MPS disorders are multi-organ
diseases, their management requires a coordinated multi-disciplinary approach. Here we discuss the unique
pattern of medical issues and multi-organ involvement in adult patients with MPS and identify the challenges
that are associated with management of MPS. This review is based on information from an expert investigator
meeting with MPS specialists held October 2–4, 2014 in Dublin, Ireland, as well as on current literature searches
focusing on MPS and adults.
© 2016 The Authors. Published by Elsevier B.V. on behalf of European Federation of Internal Medicine. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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The mucopolysaccharidoses are caused by deﬁciencies in enzymes
involved in the sequential degradation of glycosaminoglycans (GAGs,
hydrophilic polymers of highly modiﬁed hexose saccharides), which
are ubiquitous in connective tissues. The resulting impaired degradation
of GAGs in cells and tissues leads to substrate accumulation causing
progressive multi-organ dysfunction [1]. Seven types of mucopoly-
saccharidosis (MPS) disorders have been described (Table 1), with
MPS III and MPS IV each having two or more biochemical subtypes
[1,2]. MPS I can be subdivided in three subtypes according to severity:
Hurler syndrome (most severe), Hurler–Scheie syndrome, and Scheieon of Internal Medicine. This is an open access article under the CC BY-NC-ND license
Table 1
Overview of the mucopolysaccharidoses. Adapted from Muenzer et al, 2011 [1,2], with permission.
Eponym Deﬁcient enzyme Storage material
MPS I Hurler, Hurler–Scheie, Scheie α-L-iduronidase Dermatan sulfate, heparan sulfate
MPS II Hunter Iduronate-2-sulfatase Dermatan sulfate, heparan sulfate
MPS III Sanﬁlippo A: heparan N-sulfatase
B: α-N-acetylglucosaminidase
C: acetyl-CoA: α-glucosaminide acetyltransferase
D: N-acetylglucosamine 6-sulfatase
Heparan sulfate
MPS IV Morquio A: N-acetylgalactose 6-sulfatase
B: β-galactosidase
A: Keratan sulfate, chondroitin sulfate
B: Keratan sulfate
MPS VI Maroteaux–Lamy Arylsulfatase B Dermatan sulfate, chondroitin sulfate
MPS VII Sly β-Glucuronidase Dermatan sulfate, heparan sulfate, chondroitin sulfate
MPS IXa Hyaluronidase deﬁciency Hyaluronidase Hyaluronan
a Described in only four patients to date [2].
Fig. 1. Typical appearance of adults with severe forms of (left) MPS IVA showing short stature with short trunk and neck, profound skeletal and joint abnormalities and (middle) MPS VI
showing short stature, broad or thickened facial features, and small hands showing some clawing. Right: patient with a non-classical phenotype of MPS IVA showing normal stature
(reproduced from Hendriksz et al. [6], with permission).
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neurological forms of MPS II.
All MPS disorders follow an autosomal recessive inheritance pattern,
with the exception of MPS II, which is X-linked. Patients with MPS pro-
gressively develop growth impairment and deﬁciencies in respiratory,
cardiovascular, musculoskeletal, nervous, gastrointestinal, auditory,Table 2
Clinical manifestations and medical issues of the mucopolysaccharidoses and adult specialists
[1,7–14].
Common clinical manifestations
and medical issues
Musculoskeletal manifestations: deformities of the spine, thoracic cage, hips, knees, skull,
stature, joint abnormalities, joint pain, joint restriction/hypermobility
Spinal cord issues: spinal instability, cord compression, myelopathy
Ear, nose, throat manifestations, speech problems
Respiratory manifestations: upper and/or lower airway obstruction, restrictive disease, sleep-d
Cardiac manifestations: aortic and mitral valve insufﬁciency / stenosis, left ventricular hyp
diastolic function, pulmonary hypertension
Ocular manifestations: corneal clouding, refractive errors, glaucoma, papilledema
Cognitive decline, loss of motor function, behavioral problems, epilepsy
Abdominal manifestations: hepatomegaly, splenomegaly, umbilical/inguinal hernias, chro
Papular pearly rash across the scapulae, dermal melanocytosis, hirsutism
Carpal tunnel syndrome
Dental abnormalities: widely spaced and/or abnormally shaped teeth, weak enamel, gingi
Frequent surgery, diagnostic procedures requiring anesthesia
Follow-up of late effects/complications related to hematopoietic stem cell transplantation
Reduced quality of life, depressed feelings
Coordination of careand visual systems (Fig. 1, Table 2). Patients with MPS I, II, III,
and VII may also exhibit learning difﬁculties and neurological decline
[1]. Although MPS IV and VI are generally considered not to affect
neurocognitive development, some patients may have an IQ below the
normal range [3,4]. It remains to be elucidated if this is a direct result
of the disease or indirectly results from reduced school attendance orwho may be involved in the evaluation and/or management care of these manifestations
MPS types Adult specialist
and/or hands, short All types Orthopedist, rheumatologist,
physiotherapist
I, II, IV, VI Neurologist, spine orthopedist,
neurosurgeon, anesthesiologist
All types Otolaryngologist, speech therapist
isordered breathing All types Otolaryngologist, pulmonologist,
spine orthopedist
ertrophy, abnormal All types Cardiologist, intensivist,
anesthesiologist
All types Ophthalmologist
I (mainly Hurler,
Hurler–Scheie),
severe II, III, VII
Neurologist, psychiatrist,
neuropsychologist
nic diarrhea All types Gastroenterologist, general surgeon
II, III, VI Dermatologist
I, II, VI Neurologist, hand surgeon
val hyperplasia I, II, IV, VI, VII Dentist
All types Anesthesiologist
Mainly MPS I-Hurler Bone marrow transplant specialist
All types Psychologist, psychiatrist
All types Clinical geneticist, metabolic
physician, general physician
Fig. 2.Mean age of death is increasing in several MPS types: (a) Mean age at death over time between 1975 and 2010 in patients with MPS IVA A (N= 27). Reproduced from Lavery and
Hendriksz [17], with permission from Springer. (b) Survival curves for 129MPS II patients from the Hunter Outcome Survey according to the time period in which they died (in or before
1985 (N = 34) or after 1985 (N = 95). Reproduced from Jones et al [15], with permission from Springer.
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respect to genotype, clinical presentation, and progression rate,
representing a disease continuum from slow or attenuated to rapid dis-
ease progression. Patients with rapidly progressing MPS experience
symptoms in a wide range of organ systems and clinical recognition is
therefore early; patients with attenuated forms and less obvious clinical
manifestations may not be diagnosed until they reach adolescence or
adulthood [5].
Individuals with MPS, particularly those with rapidly progressing
variants, have historically experienced a shortened lifespan, with
many dying during childhood or adolescence. As a result, adults
once represented a very small percentage of the MPS population
consisting mainly of those with a more slowly progressing disease
phenotype. However, studies in MPS II and MPS VI patients show a
trend towards longer survival over recent decades (1990s–2010s)
(Fig. 2) [15,16]. Several factors may explain this trend, including
improved early diagnosis, earlier recognition of patients with slower
disease progression, advances in supportive, multi-disciplinary care,
increased awareness of disease manifestations and anesthetic risks,
and the introduction of effective systemic therapies including en-
zyme replacement therapy (ERT) and hematopoietic stem cell trans-
plantation (HSCT). It can be expected that the current trend towards
longer survival will continue and that MPS will become an important
chronic adult medical issue.
Despite increased interest in rare diseases among clinicians and
researchers, published literature on adults with MPS remains limit-
ed. Although several studies in large groups of MPS patients exist
[7,9,10,18–22], adults make up only a small portion of these study
populations. This review discusses the unique medical issues of
adults with MPS based on information from presentations and dis-
cussions among 53 participants (including pediatric subspecialists,
medical geneticists, adult MPS specialists, nurses, and patients)
who met on October 2–4, 2014, in Dublin, Ireland, and on additional
relevant literature selected by the specialists and a search in
PubMed using search terms “(mucopolysaccharidoses[MeSH Terms])
AND (adult OR age)” performed in January 2015 with ﬁlter “English
and humans” (1078 results). This review focuses on patients with
intact cognition. It should be noted that cognitive impairment can
greatly affect clinical care and outcomes of therapies discussed in
this review.
2. Multi-disciplinary management
MPS disorders are multi-organ diseases that require multi-
disciplinary management involving clinical geneticists, metabolic phy-
sicians, orthopedists, general surgeons, neurosurgeons, pulmonologists,
cardiologists, neurologists, anesthesiologists, otolaryngologists,
ophthalmologists, dentists, transplant physicians, psychiatrists, andphysiotherapists (Table 2). The management of MPS in an adult clin-
ical setting creates challenges due to the patients' short stature and
medical complexity, the fact that most internists are unfamiliar
with MPS disorders, and the limited availability of assistance for
multi-disciplinary patient care (coordination of timely, patient-
friendly, integrated care by different specialists) in adult clinics.
Internists should be aware of the special needs of MPS patients. A
proper program is required to guide young adults with MPS from
pediatric to adult health care systems, ensuring routine review and
preserving of important clinical information and experiences [23,24].
A coordinating physician (generally a clinical geneticist, metabolic phy-
sician, or general physician) can help streamline adult care by organiz-
ing a multi-disciplinary team of adult specialists around the patient.
This entails proper training and commitment of specialists to the evalu-
ation and care of MPS patients. The coordinating physician should
ensure the patient's autonomy and self-determination prevail in deci-
sion making and barriers to care and issues arising from the patient's
health-related quality of life (QoL), independence, and daily functioning
are properly addressed.3. Systemic therapies
MPS-speciﬁc therapies include ERT and HSCT. In the past decade,
the use of recombinant human ERT has become awidely available treat-
ment for MPS I, II, IVA, and VI. Clinical trials of ERT for MPSVII and MPS
IIIA are ongoing [25,26]. ERT has been shown to have favorable effects
on urinary GAG levels, endurance, respiratory function, range of joint
motion, hepatomegaly, growth (height), and cardiac function [27–31].
In addition, one study recently suggested a signiﬁcant survival beneﬁt
in MPS VI patients treated with ERT over ERT-naïve patients [16].
HSCT is considered the standard of care in infants with severe MPS I
(Hurler syndrome or MPS IH), positively affecting cognitive and intel-
lectual development [7]. A clear survival beneﬁt has been shown for
patients with MPS IH treated with HSCT [32]. HSCT is preferably done
as early as possible after birth, as the long-term neurocognitive progno-
sis after HSCT is predominantly determined by the degree of damage to
the central nervous system at the time of transplant [33]. Although
some case reports have also shown favorable outcomes in other types
of MPS [34–36], HSCT is primarily reserved for MPS IH (associated
with neurocognitive impairment) due to the inability of intravenously
infused ERT to pass the blood–brain barrier. More research is warranted
to evaluate whether the long-term advantages of HSCT outweigh its
signiﬁcant morbidity risks in other types of MPS [37].
HSCT and ERT are most effective when started early in life, before
the development of irreversible damage [1,7]. Limited data exist on
the effects of ERT when started in adulthood and more research is
warranted to ﬁll this evidence gap.
Table 3
Overview of musculoskeletal manifestations in the mucopolysaccharidoses. Reprinted from J Pediatr Rehabil Med, Volume 3, White KK and Harmatz P, Orthopedic management of
mucopolysaccharide disease, Pages 47–56, 2010, with permission from IOS Press [13].
Cervical stenosis Cervical instability Thoracolumbar kyphosis Scoliosis Hip dysplasia Genu valgum Carpal tunnel syndrome
MPS I (severe) 2+ 1+ 3+ 2+ 3+ 2+ 2+
MPS I (attenuated) 2+ 0 0 0 0 0 3+
MPS II 1+ 0 1+ 1+ 1+ 0 2+
MPS III 0 0 0 1+ 2+ 1+ 0
MPS IV 2+ 3+ 2+ 0⁎ 3+ 3+ 0
MPS VI 3+ 3+ 1+ 0 2+ 0 1+
0 = not reported; 1 = rare; 2 = common; 3 = frequent.
⁎ Kyphoscoliosis is frequently observed in patients with MPS IVA [10].
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Skeletal and joint abnormalities are observed in all MPS types [8,10,
13,38,39]. Each disorder is associated with typical radiological ﬁndings
(dysostosis multiplex) [40]; however, great phenotypic variability
exists among affected individuals (Table 3). Adult patients with severe
forms of MPS I, II, IV, VI, and VII generally show signiﬁcant bone and
joint deformities and short stature. Degenerative joint disease and
subluxation, especially of the hip joints, lumbosacral kyphosis, and
genu valgumworsen with age during childhood and, to a lesser degree,
adolescence. Bone dysplasia, which can be worsened by the abnormality
of the joint in case of subluxation or severe valgus, can ultimately lead to
painful arthritis and severe functional impairment requiring the use of a
walking aid or wheelchair. Studies have shown little effect of ERT and
HSCT on bone disease [33,41].
Joint pain is a commonmanifestation of most MPS disorders, partic-
ularly those with severe skeletal involvement. In a study including 36
children and 27 adults with MPS IVA, 74% of adult patients experienced
joint pain (versus 64% of children), most frequently in the lower
extremities [42]. Most adults (85.2%) were using a wheelchair at least
some of the time. Those adults who only required a wheelchair “when
needed” experienced more intense and widespread pain due to in-
creased mechanical joint stress associated with ambulation than adults
requiring a wheelchair all the time [42].
Several guidelines for monitoring and managing musculoskeletal
manifestations of MPS have been published [13,43–45]. These recom-
mend assessment of the hips, lower extremities, spine, and upper
limb function at diagnosis and on a regular basis (e.g. MPS II, MPS
IVA) [6,43,45] or when clinically indicated thereafter (e.g. MPS VI)
[46]. It is important that these evaluations are continued through adult-
hood. In some cases, hip dysplasia can be treated by pelvic and femoral
osteotomy or shelf acetabuloplasty. Adult patients with severe genu
valgum may beneﬁt from osteotomy [43]. However, long-term inﬂam-
matory changes and the progressive nature of MPS tend to limit the
long-term beneﬁts of these procedures [47]. Nevertheless, they may
give patients additional years of activity, comfort, and improved QoL.
In case of severe arthritis, joint replacement can be considered
[43,48,49]. The limited activity levels of adults with MPS are favorable
for the longevity of prosthetics. However, hip or knee replacement in
these patients is not straightforward and is associated with a high risk
of complications due to short stature and abnormally shaped bones,
often requiring modular or custom implants, and due to previousTable 4
Potential underlying causes of respiratory problems in patients with MPS. Adapted from Berge
Airway obstruction Restrictive disease
Narrowing of supraglottic and infraglottic airway due to
• GAG deposition and secondary inﬂammation;
• skull/spine abnormalities;
• abnormalities of trachea and main stem bronchi.
Progressive reduction of lung
• small thoracic cage;
• thoracic cage deformities
• weakness of the diaphra
• impaired diaphragm mosurgical procedures leading to less viable tissue and more scar tissue
[43]. Allograft augmentation is often required and may complicate sur-
gery. Long-term beneﬁts of hip and knee replacements in MPS patients
have not been described in the literature. Potential alternatives to sur-
gery include physical therapy and rehabilitation, use of a cane orwalker,
pain-relieving medications, or glucocorticoid (steroid) injections into
painful, inﬂamed, joints. Weight loss/control can be helpful in patients
who are overweight, which is more frequent in the MPS population.
The average body mass index of MPS patients tends to be slightly
above Centers for Disease Control and Prevention reference curves,
although still within the normal range (around 25 for MPS IVA and
around 23 for MPS VI adults) [30,38,50]. There is no clinical evidence
that supports the use of bracing in adult MPS patients [49].
Because of the high surgical (anesthetic) risk (see Respiratory
manifestations and Anesthesia below), and uncertain long-term bene-
ﬁts in adults with MPS, the experts at the meeting in Dublin recom-
mended surgery only when pain limits everyday activities, when
patients experience pain with rest, when joint stiffness limits motion,
or when anti-inﬂammatory drugs, physical therapy, or walking support
provide inadequate pain relief. The patient's QoL should always be bal-
anced against the risks of surgery/anesthesia for each case individually.
As mobility loss can negatively impact QoL [42], the patient's potential
to remain mobile should always be considered in the decision to oper-
ate. When surgery is indicated, it is important to have a surgical group
familiar with the speciﬁc surgical and anesthetic issues associated
with MPS.5. Respiratory manifestations
Respiratory impairments, including obstructive and restrictive
disease, occur in all MPS types and are among the most important
causes of mortality [15,17]. The potential underlying causes of these re-
spiratory manifestations are diverse (Table 4) [11,12]. Sleep-disordered
breathing, i.e. obstructive sleep apnea or sustained hypoventilation,
is often the ﬁrst sign of respiratory compromise [51,52]. In the long
term, sleep-disordered breathing can have cardiac consequences,
including pulmonary hypertension, cor pulmonale, and cardio-
respiratory failure [44]. Pulmonary impairment and sleep-disordered
breathing both lead to debilitating fatigue, an often underreported
manifestation of MPS. In a study in patients withMPS IVA, 63% of adults
(N = 27) reported fatigue [42].r et al [12], with permission.
Other mechanisms
volume due to
, kyphoscoliosis;
gm;
tility from enlarged liver/spleen.
• Disproportional length of trachea and spine
• Spinal cord compression
• Cardiac disease
• Central nervous system disease
• Hydrocephalus
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ment in adults withMPS but the guidelines for the evaluation andman-
agement of respiratory problems and sleep-disordered breathing in
MPS patients, published in 2013, apply for both pediatric and adult
patients [12]. It is important that adult pulmonologists are aware of
the high respiratory risk associated withMPS. If not properly evaluated,
respiratory problems may go unnoticed due to respiratory dysfunction
being masked by physical inactivity.
Evaluation of respiratory function inMPS patients can be problematic
[12]. Standard values for spirometry cannot be used in patients with
short stature and pediatric-size equipment often has to be used. Certain
pulmonary function tests may not be possible due to cognitive impair-
ment or behavioral problems. Treatment is as for other forms of obstruc-
tive and restrictive pulmonary diseases and is primarily symptomatic.
For the diagnosis of sleep-disordered breathing, guidelines recom-
mend polysomnography in all patients following a diagnosis of MPS,
then repeated monitoring based on presence of snoring, excessive
daytime somnolence, development of respiratory failure, and a reduc-
tion in vital capacity [12]. Sleep-disordered breathing in adult MPS
patients can be managed with continuous positive airway pressure
(for obstructive sleep apnea) or non-invasive ventilatory support
systems (e.g., bi-level positive airway pressure, in case of nocturnal
hypoventilation) [12]. New therapies such as oral appliances (e.g. a
custom-ﬁtted mouthpiece) may also be considered for obstructive
sleep apnea without hypoventilation. Although adenoidectomy and/or
tonsillectomy are often performed (particularly in children) [53], there
is currently a lack of conclusive evidence of beneﬁt frompublished post-
operative results. These interventions may be only partially successful
due to abnormal surrounding tissues. Patients may also beneﬁt from
reduction of the tongue (orthognathic surgery), but this has not been
described so far.
Tracheostomy should only be considered when other therapies
have failed and deferred until absolutely needed. Although immediately
life-saving, it is considered an indicator of rapid deterioration and
increasing mortality. Tracheostomy is associated with a high risk of
complications, such as tracheitis, mucous plug obstruction, or accidental
decannulation, and can interfere considerably with activities of daily
living, such as working, shopping, and traveling, and requires regular
tracheostomy care, suctioning, inhaled medications and other relat-
ed supplies [12]. However, when indicated, proper training and sup-
port can help to maintain or increase the patient's QoL. In particular,
preservation of speech and the ability to eat has been shown to be
important.
6. Ear, nose, and throat manifestations
MPS patients frequently develop progressive hearing loss due to
chronic otitis media [54,55]. Whereas young children experience con-
ductive hearing loss, adolescent and adult patients tend to develop
mixed hearing loss or pure sensorineural hearing loss [56]. Although
pressure equalization tubes (grommets) are often used in MPS patients
with otitis media, hearing loss is usually not resolved. Hearing aids
(behind the ear, bone anchored, or traditional bone hearing aids) may
improve hearing. A case review of the ﬁrst cochlear implants in two
MPS childrenwith profound sensorineural hearing loss recently report-
ed beneﬁt in terms of auditory performance and speech perception [57].
The advantages of this procedure should be balanced against anesthetic
risks and the prohibition of magnetic resonance imaging use in patients
with cochlear implants. Nerve compression from GAG storage at the
internal auditory canal can reduce the efﬁcacy of cochlear implants.
Oral manifestations in MPS patients include gingival hyperplasia,
macroglossia, swelling of adenoids and/or tonsils, and impaired opening
of the mouth [54]. Mechanical extrinsic compression, intrinsic factors
(GAG deposits in the tongue and possibly the esophagus), abnormal
nerve function, and/or cognitive issues, can lead to swallowing prob-
lems. Hearing impairment and mechanical alterations to the larynxcommonly cause speech problems [14,58]. Poor communication due
to hearing and speech problems can lead to depression, isolation, and
less participation in care.7. Cardiac manifestations
Cardiac abnormalities are a major cause of mortality in untreated
MPS patients [15,17,19]. Several studies have described the cardiacman-
ifestations of MPS, with some providing combined information on both
adults and children [59–62]. Cardiac manifestations occur inmost adults
with MPS I, II, and VI [8,18,38] but have also been described for other
types of MPS [63,64]. Progressive aortic and mitral valve insufﬁciency
and stenosis, left ventricular hypertrophy, and abnormal diastolic
function are most common [65,66]. Patients with dermatan sulfate
GAG accumulation (MPS I, II, VI) have the highest incidence of
valve abnormalities [59]. MPS individuals with slowly progressing
disease may have severe cardiac valve pathology with few other
expressions of the disease [67]. Studies have reported cardiac valve ab-
normalities in the majority of adult patients with slowly progressing
MPS I (Scheie syndrome) [18,68] and in all adult patients with slowly
progressing MPS VI [67,69].
Less common cardiac manifestations in adult MPS patients are
conduction problems (arrhythmia, complete heart block), left ventricu-
lar aneurysms, cardiomyopathy, and coronary artery disease [70–74].
Although cardiac manifestations have only been reported occasionally
for MPS III [75], severe life-threatening cardiac problems may occur in
these patients as well [70]. Evidence suggests pan-arterial storage of
GAGs in all MPS types, as conﬁrmed by an increase in carotid intima-
media thickness and arterial dysfunction (increased aortic stiffness,
poor endothelial function) versus healthy controls [8,76–79]. Because
of this phenomenon, which manifests in childhood and, in untreated
individuals, worsens with age, MPS patients tend to exhibit an arterial
age comparable to that of healthy subjects three times their age and fre-
quently present with increased blood pressure [8,74,78,80]. In patients
with short stature, blood pressure is often difﬁcult tomeasure accurately
in adult clinics.
The presentation, evaluation, and management of cardiac mani-
festations in MPS disorders have been discussed in detail in 2011
[65]. ERT generally does not improve cardiac valve disease, although
it may attenuate or delay valve disease progression. ERT may, how-
ever, have a positive impact on left ventricular hypertrophy [66]
and ventricular function [81]. HSCT in MPS IH patients does not
reverse valve disease but may attenuate progression and preserve
ventricular function [82]. Although there is variation between and
within MPS types and types of intervention, the existing literature
suggests that the maximal impact of ERT and HSCT on cardiac valves
may decrease as patients age [31].
Successful valve replacement surgery has been reported in adults
with all MPS types except MPS III [65]. Complications may occur during
cardiothoracic surgery apart from associated anesthetic risks (discussed
below). Thick, small, ﬁbrotic valve annuli can complicate native valve
removal, thus prolonging cardiopulmonary bypass time [83]. Myocardi-
al preservation may be difﬁcult in hypertrophied ventricles and GAG-
laden coronary vessels. Rehabilitation may be difﬁcult in the presence
of orthopedic issues. Successful trans-catheter aortic valve replacement
has been reported in a 30 year old with MPS I and may alleviate many
major surgical issues [84], but the relatively shortened lifespan of such
bioprosthetic valves may limit their usefulness in young adults. Cardio-
myopathy is an uncommon ﬁnding in adult MPS, although cardiac
transplantation has been performed in two individuals [85,86]. Despite
the known involvement of the coronary arteries inMPS, coronary artery
bypass in an adult has only been reported once [87]. Myocardial infarc-
tion has been occasionally described at post mortem examination in
untreated MPS adults [88] and twice in adults who had recently
begun ERT [73,89].
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Spinal instability and cord compression are common in MPS patients
(Tables 2, 3). Spinal cord compression may occur at the cranio-cervical
junction, the subaxial cervical spine, and the thoracic or lumbar spine
[90,91]. It can be due to spinal canal stenosis caused by small, thickened
posterior elements, odontoid hypoplasia, thickening of soft elements
(dura, ligamentum ﬂavum, cruciate ligaments), disc bulging, deformities
such as kyphosis or scoliosis, or a combination of these factors. MPS IVA
patients are most prone to atlantoaxial instability, due to a combination
of dens hypoplasia and ligamentous laxity [44,92]. Studies focusing on
spinal cord compression in adult patients are limited [69,93]. TheMorCAP
natural history study reported cervical myelopathy or cord compression
in 55% of MPS IVA patients N18 years [10]. In a case series describing
nine untreated MPS VI patients aged 19–29 years, spinal cord compres-
sion was present in three patients [69]. In a study including 16 children
and 15 adults with MPS VI, patients with slowly progressing disease
mostly required ﬁrst cranio-cervical decompression surgery during ado-
lescence or adulthood (median age 24 years); patients with rapidly
progressing disease had ﬁrst surgery at a median age of 12 years [94].
Guidelines for the evaluation and management of spinal cord com-
pression in patients with MPS VI and IVA were published in 2012 and
2013, respectively [90,91]. Recently, a group of experts also published
consensus recommendations for the early identiﬁcation and manage-
ment of spinal cord compression in MPS IVA patients, including a list
of routine and preoperative assessments [92].Most of the recommenda-
tions are applicable to both pediatric and adult MPS patients.
Adult neurosurgeons and spine orthopedists often have little or no
training in spinal issues in MPS patients. An internet-based anonymous
survey among 20 pediatric and adult neurosurgeons and spine orthope-
dic surgeons practicing in different countries showed that only one
of the six adult specialists who completed the questionnaire reported
having experience with MPS patients. Thirty percent of the 20 special-
ists indicated that they had treated MPS patients aged ≥18 years . In
40% of these cases, this concerned a re-intervention from procedures
performed at a younger age, underscoring the high risk of recurrence
in these patients. Most respondents indicated that care by an interdisci-
plinary team (at a center of excellence) with participation of pediatric
and adult specialists with experience in metabolic disorders and spinal
cord issues would be the best approach to manage MPS patients with
spinal cord issues.
9. Ocular manifestations
Ocular manifestations occur in all MPS types but are most prevalent
inMPS I, VI, and VII [95–97]. Progressive corneal clouding and refractive
error problems are most common with glaucoma, retinopathy, in-
creased intraocular pressure, optic disc swelling, and optic atrophy
also being described. Ocular manifestations can lead to visual impair-
ment, visual ﬁeld constriction, night blindness, or photosensitivity [95,
96,98]. As vision loss can considerably affect patients' independence
and QoL, managing ocular manifestations is important. An overview
of ocularmanifestations inMPS patients and recommendations for eval-
uation andmanagementwere published in 2010 [96]. Fahnehjelm et al.
(2012) published guidelines for the diagnosis and management of
ocular manifestations in children with MPS [97] and most also apply
to adults. These guidelines recommend assessment of ophthalmological
function at diagnosis. Routine follow-up by an ophthalmologist is not
recommended for adults [97]. However, a regular basic evaluation of
vision and ophthalmological abnormalities is recommended as part
the general routine physical examination [6].
10. Anesthesia
MPS patients frequently require general anesthesia for diagnostic
imaging and surgical procedures (correction of spinal deformities,acetabular hip dysplasia or genu valgum, corneal transplant, myrin-
gotomy with placement of pressure equalization tubes, spinal decom-
pression surgery, tonsillectomy, adenoidectomy, hernia repair) [27,
99]. Longer life expectancy may lead to an increase in the number of
surgical re-interventions, a trend which is already evident today. In
the Hunter Outcome Survey, themedian number of surgical procedures
per patient increased from two in those who died before 1985 to ﬁve in
those who died since 1985 [15].
Potential anesthetic problems are numerous and encompass not
only the surgical procedure itself but also sedation thatmay be required
for preoperative investigations. Abnormal anatomical features and tis-
sue deposits can lead to airway, cardiac, intravenous access, and cervical
spine problems. Typical airway complications that can arise during
anesthesia include difﬁculties with bag mask ventilation, intubation/
extubation problems, subglottic stenosis, and profuse and thick secre-
tions [100]. Spinal cord compression or atlantoaxial instability also
increase anesthetic difﬁculty; the former because of the increased risk
of potential spinal cord ischemia during hypotensive episodes during
surgery and the latter from the risk to the cervical spinal cord during air-
way management. Cardiac problems such as pulmonary hypertension,
cardiomyopathy, and valvular disorders are compounded by difﬁculties
in accurately assessing cardiorespiratory reserve [100]. Kyphoscoliosis
may interfere with correct positioning during surgery. Behavioral and
communication problems as well as neurocognitive delay can hinder
assessment of involvement of other organ systems and the manage-
ment of induction.
The management of adults with MPS is challenging for adult anes-
thetists as the patients' short stature means that pediatric equipment
is often required. The variable nature of MPS implies that no two
patients present with identical problems; what works for one patient
may not work for another. As risk factors such as airway difﬁculties
worsen with age [101], previously successful anesthesia does not guar-
antee success with future re-interventions. For most adult anesthetists,
MPS cases are extremely rare; therefore,more time is needed for preop-
erative assessment and planning. Although past anesthetic charts can
identify potential problems and solutions, ametabolic physician or clin-
ical geneticist may be a better important source of information about
exercise tolerance, the results of sleep studies and cardiac investiga-
tions. Anesthetic risk factors in MPS disorders and recommendations
for presurgical planning and pre-, peri-, and postsurgical management
have been discussed in detail [100,102]. Potential risks and beneﬁts of
procedures should always be discussed with the patient before surgery,
including the possibility of emergency tracheostomy as a life-saving
measure. Because of the high risk of difﬁcult intubation, paralysis and
death, anesthesia in MPS patients should only be planned in tertiary
care hospitals that have the expertise to manage anticipated problems.
The results of a survey of the 1900 Difﬁcult Airway Society members
(UK) presented by Dr. James Palmer during the Dublin expert meeting
summarized the limited experience of anesthetists in treating adults
with MPS and the high anesthetic risk in these patients. The survey
was worded so that clinicians who had no experience with MPS exited
the survey immediately. Of the 242 respondents who had any experi-
ence with MPS, only 34 (14%) had experience of adult MPS patients,
and of these, 30 had anesthetized adult MPS patients in the past year.
Just over half had treated four cases or more, mostly patients with
MPS IV or VI. Twelve patients received general anesthesia and ﬁve re-
gional anesthesia (four with sedation). Minor airway or other problems
were reported in four patients, one patient had signiﬁcant airway dif-
ﬁculty requiring prolonged non-surgical intervention, and seven had
major airway problems requiring emergency tracheostomy. Twopatients
died. These results emphasize the necessity to include anesthesiologists
in the multi-disciplinary team of adult specialists in order to ensure that
the available knowledge about the patient is accessible to the whole
team. In this way, a group of specialists who are familiar with the unique
issues ofMPS patients during surgerywill be involved in the care of these
patients and help ensure safe surgical outcomes.
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Abdominal region complications including hepatomegaly, spleno-
megaly, and umbilical or inguinal hernias have been described in all
MPS types [7–10]. Although hernias can be surgically repaired, they
often recur [6].
Carpal tunnel syndrome or trigger ﬁngers frequently occur in
MPS I, II, and VI [13,103,104]. Whereas splinting and non-steroidal
anti-inﬂammatory drugs may be considered for symptomatic treat-
ment of mild cases of carpal tunnel syndrome, surgery (median
nerve release) is indicated in cases with clinical and electrodiagnostic
evidence of compressive neuropathy [103]. The risk of recurrent carpal
tunnel syndrome after surgery in MPS patients has not been deﬁned
as yet.
Dental abnormalities (widely spaced teeth with structurally weak
enamel, small pointed cusps, spade-shaped incisors, pitted buccal
surfaces, gingival hyperplasia) have been described for MPS IVA and
MPS VI but appear to be less common in other types of MPS [44,105].
Fluoride supplementation can help to prevent caries. Fissure sealing of
dentition may be considered in some cases [6]. Dermatological prob-
lems occur in MPS II, MPS III, and MPS VI [1,8,20,106] (Table 2).
12. Conclusions
Historically, patients with MPS have primarily been cared for by
pediatric specialties. However, with more effective therapy and sup-
portive care, there is an evolution towards an increasing population of
MPS patients that will require chronic care as adults. This will create
new challenges for adult primary care providers and specialists treating
these individuals. It is expected that the number of MPS adults, as well
as the likelihood of encountering such patients in an adult specialist's
practice, will further increase in the coming years. To provide optimal
care, it will be critical to continue routine evaluations of the clinical
manifestations of MPS throughout adulthood. Surgical procedures in
adult MPS patients may be complicated by several factors, including
short stature, bone deformities, obstructive and restrictive airway prob-
lems, and increased anesthetic risk. Thus, an individualized approach
that balances beneﬁts and risks of surgical procedures is required. To
improve the management of MPS in adulthood, the modiﬁed natural
history of these disorders should be systematically captured, and more
clinical studies should include, and focus on, adult patients. There is
also a need for programs guiding transition from pediatric to adult
health care and for a medical home or coordinating physicians who
can monitor disease management and progression. Development of
adult rare disease clinics as well as inclusion of treatable rare dis-
eases into training programs in adult medicine may help improve
outcomes for adult MPS patients [107]. The importance of manage-
ment teams composed of health care specialists who are properly
trained to meet the speciﬁc, unique, medical needs of MPS patients
should be stressed.
Learning points
• The MPS disorders are caused by deﬁciencies in enzymes involved
in GAG catabolism, leading to growth retardation and progressive
damage to respiratory, cardiovascular, musculoskeletal, nervous, gas-
trointestinal, auditory, and visual systems.
• Better methods for diagnosis, multi-disciplinary care, and new thera-
pies have extended lifespan, leading to an increasing number of adults
with MPS.
• Optimal care for adults with MPS requires:
o Programs guiding transition from pediatric to adult health care
o Continuation of routine evaluations of clinical manifestations
throughout adulthood
o Amedical home or coordinating physicianswho canmonitor disease
progression and streamline disease managemento Management teams composed of health care specialists properly
trained to meet the speciﬁc, unique, medical needs of adult MPS
patients
o Development of adult rare disease clinics and inclusion of treatable
rare diseases into training programs in adult medicine
o More studies focusing on adult MPS patientsConﬂicts of interest
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